GroPep starts Phase 1 infertility trial

sponsible for instructing the mother's immune system to tolerate the implanting embryo. Preclinical studies previously reported by GroPep have shown that a single intravaginal dose of PV903 halves the miscarriage rate in a mouse model of reproductive failure that shares many features with recurrent miscarriage in humans. A Clinical Research Study conducted in the last six months has enabled GroPep to identify and measure a range of immune cells from the cervix of healthy women volunteers. Changes in these cells after the introduction of PV903 are expected to indicate whether the treatment is effective. GroPep CEO Mr Bob Finder said he was delighted at the commencement of the PV903 clinical trial. He further noted, "This trial represents the culmination of several years work by GroPep and our collaborators to understand the role of PV903 in immune-based infertility, undertake toxicology studies and develop a stable gel-based formulation."

"As this is a potential first-in-class product, GroPep has had to develop new methods to measure the effect of PV903 on the immune system. We are now in a position to initiate the clinical phase of this program, which has the potential to offer the first drug treatment for recurrent miscarriage", Mr Finder added. The following information is provided regarding the trial. Name of Trial

A Phase Ia, randomised, double-blind, placebo-controlled, sequential single-dose escalating trial in healthy adult female volunteers to evaluate the short-term safety, tolerability and preliminary immune activity of vaginally administered PV903 gel.


Contact: Mr Tony Mitchell
Research Australia

Page: 1 2

Related medicine news :

1. GroPep awarded key patent for infertility treatment in Europe
2. GroPep completes final milestone of the path malaria vaccine initiative
3. GroPep to pursue promising asthma drug following preclinical study results
4. GroPep licenses technology to TGR BioSciences
5. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
6. Coffee jump-starts short-term memory
7. Epidemiology in Europe: the problem starts in childhood
8. GSK announces launch of largest ever Phase III trial in lung cancer treatment
9. Phase II study shows combination improves survival of metastatic melanoma patients
10. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
11. Drug combination proves effective against myeloma in Phase I trial

Post Your Comments:

(Date:8/3/2020)... ... August 03, 2020 , ... WorkBook6 – a Tempe, Arizona-based ... The site provides a simple and efficient way for Americans over the age ... as an important expansion for the insurance marketing ecosystem, and a critical service ...
(Date:7/31/2020)... ... July 31, 2020 , ... Leaders of the Operation ... site in Savannah, GA. Visitors included Moncef Slaoui, chief advisor, and General Gustave ... announced the OWS program to accelerate the development, manufacturing, and distribution of COVID-19 ...
(Date:7/31/2020)... ... July 31, 2020 , ... National Association of Chain Drug ... regarding the nation’s ongoing preparations for the eventual deployment of COVID-19 vaccines: , ... effective and essential component of vaccine deployment. They will need to be part ...
(Date:7/22/2020)... ... July 22, 2020 , ... ... Lives Matter movement, the world has changed, and there’s no going back. In ... While coping mechanisms help us temporarily manage emotional struggles, healing is the approach ...
(Date:7/22/2020)... Okla. (PRWEB) , ... July 22, 2020 , ... ... today announced the launch of its new Data Curation as a Service (DCaaS) ... use case modules focus on specific clinical data curation parameters and are custom ...
Breaking Medicine News(10 mins):
(Date:7/22/2020)... ... , ... Local animal nutrition expert, Dr. Anoosh Rakhshandeh, and his wife, Dr. ... supplies company – Pet Wants Lubbock. , Pet Wants’ specially-crafted, private-label pet food formulas ... for a complete and balanced diet in every bite. Pet Wants Lubbock has multiple ...
(Date:7/18/2020)... ... , ... A Perspective essay published in Psychosomatics: ... among psychiatrists and other clinicians can affect patient-clinician communication and diminish the quality ... authored by researchers at The Fenway Institute and Massachusetts General Hospital and adds ...
(Date:7/10/2020)... (PRWEB) , ... July 10, 2020 , ... ... developed new guidance for HIPAA Compliance for Business Associates. Business associates create, receive, ... entity clients. As such, business associates are required to be HIPAA compliant, ensuring ...
Breaking Medicine Technology:
Cached News: